Disc Medicine, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Disc Medicine, Inc. (IRON) had Restructuring and Related Cost, Number of Positions Eliminated of 24 Positions as of 2022-02-28, per its 10-Q filed 2022-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2022-11-10
- 2022-02-28: Restructuring and Related Cost, Number of Positions Eliminated 24.00 Positions.
- 2021-10-31: Restructuring and Related Cost, Number of Positions Eliminated 1 month 11.00 Positions.
- 2021-10-04: Restructuring and Related Cost, Number of Positions Eliminated 11.00 Positions.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated | Restructuring and Related Cost, Number of Positions Eliminated 1 month |
|---|---|---|
| 2022-02-28 | 24.00 Positions 10-Q · filed 2022-11-10 | |
| 2021-10-31 | 11.00 Positions 10-Q · filed 2022-11-10 | |
| 2021-10-04 | 11.00 Positions 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |